


Figure 1

Compound No.	Structure
1	 (AZD1775)
2	NUV-569
3	IMP7068
4	Debio 0123
5	 (SC0191)
6	 (PD0166285)



% Inhibition
0
10
20
30
40
50
60
70
80
AZD1775 50nM
AZD1775 100nM
AZD1775 300nM
Compound A 12nM
Compound A 4nM
Compound A 1nM
Compound A 12nM + AZD1775 50nM
Compound A 4nM + AZD1775 50nM
Compound A 1nM + AZD1775 50nM
Compound A 12nM + AZD1775 100nM
Compound A 4nM + AZD1775 100nM
Compound A 1nM + AZD1775 100nM
Compound A 12nM + AZD1775 300nM
Compound A 4nM + AZD1775 300nM
Compound A 1nM + AZD1775 300nM

Figure 2



Vehicle qd × 28 p.o.
AZD1775 80 mg/kg qd × 13 (PG-D0-D12) qd × 5 (PG-D17-D21) p.o.
Compound A 10 mg/kg qd × 28 p.o.
AZD1775 80 mg/kg + Compound A 10 mg/kg qd × 28 p.o.
Tumor Volume (mm3)
700
600
500
400
300
200
100
0
-1
2
5
8
11
14
17
20
23
26
29
Days Post Treatment

Figure 3